Botanix Pharmaceuticals Back On Track With Reduced Cash Burn, Euroz Hartleys Says

MT Newswires Live

Oct 20, 2025

Botanix Pharmaceuticals (ASX:BOT) is back on track following the release of its fiscal first quarter results, with reduced cash burn alleviating funding concerns, Euroz Hartleys said in a Monday note.

The reported revenue of AU$7.1 million for its Sofdra topical gel, up from AU$4.3 million in the previous quarter, while total prescriptions shipped for Sofdra rose to 20,418 in the quarter, up from 13,647 last quarter.

The results broadly came in line with or exceeded expectations for the quarter, with Euroz Hartleys expecting 20,100 in total prescriptions and AU$7.5 million in net revenue.

Supported by findings from a recent US dermatologist survey and benchmarking against prior launches, Sofdra has the potential to become the category leader in hyperhidrosis, a medical condition in which a person sweats excessively, according to the investment advisory firm.

Euroz Hartleys maintained its buy recommendation and AU$0.44 price target on Botanix Pharmaceuticals.

Botanix Pharmaceuticals shares rose 7% in afternoon trade on Monday.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2576866058"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2576866058\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2576866058?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-10-20 10:45","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2576866058","market":"sg","top_or_hot":-1,"title":"Botanix Pharmaceuticals Back On Track With Reduced Cash Burn, Euroz Hartleys Says","media":"MT Newswires Live","content":"<html><body><p> <a href=\"https://laohu8.com/S/BOT.AU\">Botanix Pharmaceuticals</a> (ASX:BOT) is back on track following the release of its fiscal first quarter results, with reduced cash burn alleviating funding concerns, <a href=\"https://laohu8.com/S/EZL.AU\">Euroz</a> Hartleys said in a Monday note.</p><p>The reported revenue of AU$7.1 million for its Sofdra topical gel, up from AU$4.3 million in the previous quarter, while total prescriptions shipped for Sofdra rose to 20,418 in the quarter, up from 13,647 last quarter.</p><p>The results broadly came in line with or exceeded expectations for the quarter, with Euroz Hartleys expecting 20,100 in total prescriptions and AU$7.5 million in net revenue.</p><p>Supported by findings from a recent US dermatologist survey and benchmarking against prior launches, Sofdra has the potential to become the category leader in hyperhidrosis, a medical condition in which a person sweats excessively, according to the investment advisory firm.</p><p>Euroz Hartleys maintained its buy recommendation and AU$0.44 price target on Botanix Pharmaceuticals.</p><p>Botanix Pharmaceuticals shares rose 7% in afternoon trade on Monday.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Botanix Pharmaceuticals Back On Track With Reduced Cash Burn, Euroz Hartleys Says</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBotanix Pharmaceuticals Back On Track With Reduced Cash Burn, Euroz Hartleys Says\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2025-10-20 10:45</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> <a href=\"https://laohu8.com/S/BOT.AU\">Botanix Pharmaceuticals</a> (ASX:BOT) is back on track following the release of its fiscal first quarter results, with reduced cash burn alleviating funding concerns, <a href=\"https://laohu8.com/S/EZL.AU\">Euroz</a> Hartleys said in a Monday note.</p><p>The reported revenue of AU$7.1 million for its Sofdra topical gel, up from AU$4.3 million in the previous quarter, while total prescriptions shipped for Sofdra rose to 20,418 in the quarter, up from 13,647 last quarter.</p><p>The results broadly came in line with or exceeded expectations for the quarter, with Euroz Hartleys expecting 20,100 in total prescriptions and AU$7.5 million in net revenue.</p><p>Supported by findings from a recent US dermatologist survey and benchmarking against prior launches, Sofdra has the potential to become the category leader in hyperhidrosis, a medical condition in which a person sweats excessively, according to the investment advisory firm.</p><p>Euroz Hartleys maintained its buy recommendation and AU$0.44 price target on Botanix Pharmaceuticals.</p><p>Botanix Pharmaceuticals shares rose 7% in afternoon trade on Monday.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK7096","symbol_name":"制药","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2576866058","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2576866058","pubTimestamp":1760928350,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Botanix Pharmaceuticals (ASX:BOT) is back on track following the release of its fiscal first quarter results, with reduced cash burn alleviating funding concerns, Euroz Hartleys said in a Monday note.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK7096":"制药","BK7502":"大麻概念","BOT.AU":"BOTANIX PHARMACEUTICALS LTD","BK7508":"医药生物股"},"translate_title":"Euroz Hartleys表示，Botanix Pharmaceuticals重回正轨，现金消耗减少","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BOT.AU":1},"content_text":"Botanix Pharmaceuticals (ASX:BOT) is back on track following the release of its fiscal first quarter results, with reduced cash burn alleviating funding concerns, Euroz Hartleys said in a Monday note.The reported revenue of AU$7.1 million for its Sofdra topical gel, up from AU$4.3 million in the previous quarter, while total prescriptions shipped for Sofdra rose to 20,418 in the quarter, up from 13,647 last quarter.The results broadly came in line with or exceeded expectations for the quarter, with Euroz Hartleys expecting 20,100 in total prescriptions and AU$7.5 million in net revenue.Supported by findings from a recent US dermatologist survey and benchmarking against prior launches, Sofdra has the potential to become the category leader in hyperhidrosis, a medical condition in which a person sweats excessively, according to the investment advisory firm.Euroz Hartleys maintained its buy recommendation and AU$0.44 price target on Botanix Pharmaceuticals.Botanix Pharmaceuticals shares rose 7% in afternoon trade on Monday.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}